Statin–Ezetimibe Therapy and Incident Myocardial Infarction Across Modified Cardiovascular–Kidney–Metabolic Risk Groups: A Nationwide Target Trial Emulation

BACKGROUND: Cardiovascular-kidney-metabolic syndrome integrates metabolic risk, kidney dysfunction, and cardiovascular disease. Whether statin-ezetimibe combination therapy is associated with lower subsequent myocardial infarction risk than statin monotherapy among patients across modified cardiovascular-kidney-metabolic risk groups remains uncertain. METHODS: Using the Korean National Health Insurance Service database, we emulated separate two-arm landmark target trials within modified early and late cardiovascular-kidney-metabolic risk groups. Adults aged 30-74 years with dyslipidemia who received prescriptions covering a total of 180 days with statin monotherapy or a fixed-dose statin-ezetimibe combination were eligible. Treatment was assigned at the 180-day landmark. Stabilized inverse probability of treatment weighting and cause-specific Cox regression were used to calculate hazard ratio (HR) and 95% confidence interval (CI), with death treated as a competing event for cumulative incidence estimation. RESULTS: Among 309,371 treated participants, 239,954 had modified early risk and 69,417 had modified late risk. Compared with statin monotherapy, statin-ezetimibe therapy was associated with lower myocardial infarction risk after weighting in both early-risk participants (HR 0.87, 95% CI 0.81-0.95) and late-risk participants (HR 0.88, 95% CI 0.79-0.98). 10-year weighted cumulative incidence was 1.97% versus 2.23% in the early-risk group and 3.52% versus 3.94% in the late-risk group. In same-intensity comparisons, the association was most evident with moderate-intensity therapy, particularly in the early CKM group (HR, 0.87; 95% CI, 0.79-0.95). CONCLUSION: Among adults with dyslipidemia who received prescriptions covering a total of 180 days, statin-ezetimibe combination therapy was associated with a lower subsequent risk of myocardial infarction than statin monotherapy across modified CKM risk groups. The association was most evident in moderate-intensity comparisons.

Authors

Institutions

Publication Details

Journal
European Heart Journal - Cardiovascular Pharmacotherapy
Published
2026-11-12
DOI
https://doi.org/10.1093/ehjcvp/pvag099
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Statin–Ezetimibe Therapy and Incident Myocardial Infarction Across Modified Cardiovascular–Kidney–Metabolic Risk Groups: A Nationwide Target Trial Emulation

Yohwan Lim, Ryuk Jun Kwon
European Heart Journal - Cardiovascular Pharmacotherapy
Lipoproteins and Cardiovascular Health
article

Statin–Ezetimibe Therapy and Incident Myocardial Infarction Across Modified Cardiovascular–Kidney–Metabolic Risk Groups: A Nationwide Target Trial Emulation

Yohwan Lim, Ryuk Jun Kwon
article en

Abstract

BACKGROUND: Cardiovascular-kidney-metabolic syndrome integrates metabolic risk, kidney dysfunction, and cardiovascular disease. Whether statin-ezetimibe combination therapy is associated with lower subsequent myocardial infarction risk than statin monotherapy among patients across modified cardiovascular-kidney-metabolic risk groups remains uncertain. METHODS: Using the Korean National Health Insurance Service database, we emulated separate two-arm landmark target trials within modified early and late cardiovascular-kidney-metabolic risk groups. Adults aged 30-74 years with dyslipidemia who received prescriptions covering a total of 180 days with statin monotherapy or a fixed-dose statin-ezetimibe combination were eligible. Treatment was assigned at the 180-day landmark. Stabilized inverse probability of treatment weighting and cause-specific Cox regression were used to calculate hazard ratio (HR) and 95% confidence interval (CI), with death treated as a competing event for cumulative incidence estimation. RESULTS: Among 309,371 treated participants, 239,954 had modified early risk and 69,417 had modified late risk. Compared with statin monotherapy, statin-ezetimibe therapy was associated with lower myocardial infarction risk after weighting in both early-risk participants (HR 0.87, 95% CI 0.81-0.95) and late-risk participants (HR 0.88, 95% CI 0.79-0.98). 10-year weighted cumulative incidence was 1.97% versus 2.23% in the early-risk group and 3.52% versus 3.94% in the late-risk group. In same-intensity comparisons, the association was most evident with moderate-intensity therapy, particularly in the early CKM group (HR, 0.87; 95% CI, 0.79-0.95). CONCLUSION: Among adults with dyslipidemia who received prescriptions covering a total of 180 days, statin-ezetimibe combination therapy was associated with a lower subsequent risk of myocardial infarction than statin monotherapy across modified CKM risk groups. The association was most evident in moderate-intensity comparisons.

European Heart Journal - Cardiovascular Pharmacotherapy
Pusan National University Yangsan Hospital (KR), Pusan National University (KR)
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon